Patterns of care and clinical outcomes in stage IVA cervical cancer: 14-year experience from a tertiary care centre in South India. (10th December 2023)

• Record Type: Journal Article
• Authors: John, Neenu Oliver; Sathyamurthy, Arvind; Prasoona, Shanthi; Ramireddy, Jeba Karunya; Rebekah, Grace; Das, Saikat; George, Reena Mary; John, Subhashini; Ram, Thomas Samuel
• Is Part Of: Journal of radiotherapy in practice. Volume 22(2023)
• Publication Date: 2023-12-10
• Subjects: Cancer Pain -- Carcinoma Cervix IVA -- Chemoradiation -- Locally Advanced Cervical Cancer -- Palliative Care; Radiotherapy -- Periodicals; 615.842005
• DOI: 10.1017/S1460396921000443
• Languages: English
• ISSNs: 1460-3969

Abstract

Abstract: Aim: To analyse the patterns of care and clinical outcomes of patients diagnosed with cervical cancer International Federation of Gynecology and Obstetrics (FIGO) stage IVA treated at a tertiary care centre in South India. Materials and methods: The electronic medical records of 2, 476 patients diagnosed with cervical cancer at a tertiary care institution between January 2005 and December 2018 were reviewed. Among them, 96 patients diagnosed with histologically proven carcinoma cervix stage IVA established by either cystoscopy or proctoscopy were included. Four patients who did not receive treatment at the study centre were excluded and 92 patients were available for final analysis. Results: The median follow-up period was 12 months (2–131 months). Of the 92 patients, 59 patients (64·13%) received radiation therapy (RT) alone, 22 patients (23·9%) received chemoradiation (CRT), three patients (3·26%) received neoadjuvant chemotherapy (NACT) followed by RT, one (1·08%) received NACT followed by CRT, four patients (4·35%) received chemotherapy alone, while three (3·26%) were offered best supportive care. The median progression-free survival (PFS) was 12 months (95% CI: 9·6–14·4 months) and median overall survival (OS) was 25 months (95% CI: 16·6–33·4 months). The 2-year and 3-year PFS was 30 and 20%, respectively, and the OS was 50 and 32%, respectively. Conclusion: The management of stage IVA cervical cancer needs to be individualised to achieve a fine balance between local control, toxicity, and quality of life. RT is the mainstay of treatment with concurrent chemotherapy in carefully selected patients. Involvement of palliative care team early in the course of treatment adds a holistic approach to the continuum of oncological care.